Cryoport updates 2025 revenue outlook to $170M-$174M while expanding global supply chain infrastructure

Q3 2025 Management View CEO Jerrell Shelton highlighted double-digit growth in both Life Sciences Services and Life Sciences Product segments, noting "revenue from our support of commercial cell and ...
Fierce Biotech

New in vivo gene editing biotech blossoms from CRISPR pioneer Jennifer Doudna's lab with $82M

A new West Coast biotech has emerged into the busy in vivo cell therapy space, this time with the backing of Nobel Prize-winning CRISPR pioneer Jennifer Doudna, Ph.D. Azalea Therapeutics has bloomed ...
GEN - Genetic Engineering and Biotechnology News

The Growing Strategic Importance of CDMOs in Cell & Gene Therapy

CDMOs must now offer platform-based manufacturing, simplified tech transfers, AI-driven automation, and robust analytical services. Speed is also critical—traditional 18–24-month timelines are no ...
MedCity News

The Discipline of Differentiation: Winning Strategies in a Crowded Cell and Gene Therapy Market

The cell and gene therapy industry has achieved breakthroughs once thought impossible, translating novel concepts into real therapeutic options for patients. The FDA has now approved 43 cell and gene ...
TMCnet

Azalea Therapeutics Launches with $82 Million Financing to Redefine Precision Genomic Medicines by Engineering Cells Directly Inside Each Patient

Azalea Therapeutics, Inc., a biotechnology company redefining precision genomic medicines in vivo, today announced its official launch and completion of $82 million in seed and Series A financing to ...
TipRanks on MSN

Precision Biotech Wave Builds As FDA Expedites Breakthrough Cell And Gene Therapies

Vancouver, Canada, November 4th, 2025, FinanceWire Equity Insider News Commentary – The precision medicine sector reached ...
Business Wire

Bayer First Company to Advance Cell Therapy as Well as Gene Therapy Against Parkinson’s Disease

First investigational allogeneic pluripotent stem cell derived therapy pivotal Phase III clinical trial exPDite-2 with bemdaneprocel started Phase II gene therapy trial REGENERATE-PD with AB-1005 ...
Health Affairs

A Private Sector Approach To Cell And Gene Therapy In The US

The rapid advancement of biomedical technologies has opened the door to curing previously untreatable diseases, offering hope for longer, healthier, and more productive lives. Innovations such as ...
STAT

Disagreements over Duchenne therapy, management style may have led to ouster of key FDA official

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...
Reuters

Focus: Parkinson's disease at forefront of Bayer bet on cell and gene therapies

Cell and gene therapies account for 20% of pipeline Parkinson's therapy bemdaneprocel in Phase 3 trial Pharma success urgently needed, says fund manager FRANKFURT, Sept 25 (Reuters) - Bayer's ...
Fred Hutch

Gene therapy delivery system successfully targets CD90+ hematopoietic stem cells in vivo

Researchers in the lab of Hans-Peter Kiem, MD, PhD, at Fred Hutch Cancer Center have devised a method that could one day treat genetic hematologic disorders by correcting how the body makes blood ...